Today, monitoring of blood cholesterol, hemoglobin A1C (HbA1c), and prostate-specific antigen (PSA), once validated, have become routine tests to evaluate risk of cardiovascular disease, diabetes, and prostate cancer, respectively. This evidence concerns the gene KLK3 and cardiovascular disorder.